Covid19 Impact on Lymphedema Diagnostics Market to Reach $ 37.6 Million Valuation by 2025, Says MRFR

Covid19 Impact on Lymphedema Diagnostics Market to Reach $ 37.6 Million Valuation by 2025, Says MRFR
Global Lymphedema Diagnostics Market Research Report: By Type (Primary, Secondary), By Technology (Lymphoscintigraphy, Magnetic resonance imaging, Computed Tomography, Ultrasound Imaging, Others), By Disease Type (Cancer, Inflammatory Diseases, Cardiovascular Disease, Others) and By End-User (Hospitals, Diagnostic Centers, Others) – Forecast to 2025

Lymphedema Diagnostics Market Overview:

The global market for the lymphedema diagnostics market has been projected to surpass a market valuation of USD 37.6 million by 2025 at a 7.1% CAGR during the forecast period of 2019 to 2025. Market Research Future (MRFR) revealed that the market could benefit from several factors like the high prevalence of the diseases, growing instances of cancer, better diagnostic facilities and demand for early diagnosis, hike in awareness level, increasing inclusion of technologies to widen the testing opportunities, investment for research and development procedures, and others. 

Free Sample Copy of Lymphedema Diagnostics Market With Considering Coivd19 Impact on this Market @ 

However, the market may suffer due to the short half-life of radiopharmaceuticals. Also, the high cost of diagnostic tests can deter the market from having a smooth growth during the forecast period.

Lymphedema Diagnostics Market Segmentation:

The global report on the lymphedema diagnostics market can be segmented into type, technology, end user, and disease type. MRFR analysts have included these segments and supported their claims with figures, charts, and graphs. 

By technology, the global market report on the lymphedema diagnostics market can be segmented into magnetic resonance imaging, lymphoscintigraphy, ultrasound imaging, computed tomography, and others. The lymphoscintigraphy segment has the maximum market share. 

By disease type, the global study includes segments like cancer, cardiovascular diseases, inflammatory diseases, and others. The cancer segment has the maximum market share.

By type, the global market can be segmented into primary and secondary. The secondary segment has the maximum market share.

By end user, the global report on the lymphedema diagnostics market can be segmented into hospitals, diagnostics centers, and others. In 2018, it was the hospital segment with the maximum market share. 

 Lymphedema Diagnostics Market Regional Analysis:

The Americas is impacting the global market with the lion’s share of the revenues that they earn from the investment taking place in mainly countries like the US and Canada. These two countries and their robust infrastructure would ensure better growth for the market. Asia Pacific would register the fastest growth during the forecast period. 

Lymphedema Diagnostics Market Competitive Landscape:

Siemens Healthineers, GE Healthcare, Stryker Corporation, Philips, Shimadzu Corporation, Canon, Inc., United Imaging Healthcare Co., Ltd., Hitachi, Ltd., and Fluoptics are some of the major companies involved in the global lymphedema diagnostics market. These companies are impacting the market growth with their top-class strategic measures that often span across types like merger, acquisition, innovation, increased funding for research and development, collaboration, branding, launching of the product, and others. MRFR recorded these moves to understand how the market may get impacted and what trends would take charge of the global market in the coming years. 


Industry News:

In June 2020, an Australian medical device maker with the permission for a device that can detect lymphedema inked a national purchase agreement with the U.S. Oncology Network. The latter is a Texas-based group with over 1,200 physicians across 470 locations. It is also a subsidiary of McKesson Corporation. Lymphedema is a type of disease where swelling takes place in arms and legs and can be a side-effect of some cancer treatments. If diagnosed early, this can be treated with good results, but its impact cannot be wholly reversed in its later stages.  

In February 2020, ImpediMed Limited (ASX.IPD), a medical software technology company, known for its non-invasive processes of measuring, monitoring, and managing of fluid status and tissue composition by using bioimpedance spectroscopy (BIS), announced that the NCCN Clinical Practice Guidelines for Breast Cancer (NCCN Guidelines®) included new recommendations for early detection and diagnosis of lymphedema to in their latest guideline to achieve optimal management.



NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India